Evidence-Based Therapy
A promising adjunctive approach in glioblastoma — supported by pre-clinical evidence, early clinical trials, and an exceptional safety profile.
Reviewed March 2026 • 15+ Peer-Reviewed StudiesThe Science
Molecular hydrogen (H₂) is a colorless, odorless gas composed of two hydrogen atoms. It is the lightest and smallest molecule in nature (molecular weight 2 Da, kinetic diameter 289 pm). Initially believed to be biologically inert, a landmark 2007 publication in Nature Medicine by Ohsawa et al. demonstrated that H₂ selectively neutralizes cytotoxic hydroxyl radicals (•OH) and peroxynitrite (ONOO⁻) — the most damaging reactive oxygen species — without interfering with beneficial signaling ROS such as superoxide and hydrogen peroxide.
Since 2007, over 2,000 scientific publications and 81+ registered clinical trials have explored hydrogen's therapeutic effects across cardiovascular, neurological, respiratory, metabolic, and oncological diseases.
2 Da
Molecular Weight
The lightest molecule in existence — easily crosses all biological membranes including the blood–brain barrier
2,000+
Scientific Publications
Peer-reviewed papers since 2007 exploring hydrogen's therapeutic effects
81+
Clinical Trials
Registered clinical trials across cardiovascular, neurological, and oncological diseases
Zero
Serious Adverse Events
No serious hydrogen-related adverse events reported across all published human studies
How It's Delivered
Hydrogen Gas Inhalation
2–67% H₂ mixed with oxygen or air, delivered via nasal cannula or mask for 1–6 hours daily. Most common in clinical research.
Hydrogen-Rich Water
0.4–2.0 ppm concentration, consumed orally at 0.5–1.5 L per day. Practical for long-term outpatient use.
Hydrogen-Rich Saline
Administered intravenously in hospital settings. Delivers hydrogen directly into the bloodstream.
Magnesium Tablets
Oral tablets that generate H₂ upon reaction with water in the stomach. Convenient for daily supplementation.
Relevance to GBM
A fundamental challenge in GBM treatment is drug delivery across the blood–brain barrier (BBB), which prevents most therapeutic agents from reaching brain tumors. Molecular hydrogen's extraordinarily small size, neutral charge, and nonpolar nature allow it to freely diffuse across all biological membranes, including the BBB, without requiring active transport mechanisms. Studies in hypertensive stroke-prone rats demonstrated that hydrogen-rich water attenuated BBB disruption through reduction of oxidative DNA damage and suppression of MMP-9 activity. This ensures hydrogen can reach intracranial tumors at therapeutic concentrations — a decisive advantage over many conventional agents.
The 2019 study by Liu et al. (Stem Cell Research & Therapy) demonstrated that inhalation of 67% hydrogen gas in a rat orthotopic glioma model and mouse xenograft model produced significant results: tumor volume reduced (223.3 ± 33.83 mm³ vs. 363.3 ± 34.80 mm³, p = 0.045), median survival increased from 28 to 31 days (p = 0.0012), Ki-67 (proliferation marker) markedly downregulated, CD34 (angiogenesis marker) significantly reduced, and migration, invasion, and colony formation inhibited in C6 and U87 glioma cells.
Glioma stem cells (GSCs) are considered the "root cells" driving GBM recurrence and resistance. Hydrogen therapy forces GSC differentiation: CD133 and Nestin (stem markers) significantly downregulated; GFAP (differentiation marker) upregulated. Self-renewal capacity suppressed in sphere-forming assays. Ma et al. (2020) showed hydrogen upregulated oligodendroglial markers (Olig1, MBP) while downregulating SOX2.
Ma et al. (2020) revealed hydrogen induces significant metabolic reprogramming in GSCs: glucose uptake and lactate production significantly reduced (Warburg effect suppression), TCA cycle intermediates decreased, de novo nucleotide synthesis promoted consistent with a shift from self-renewal toward differentiation. Hexokinase 2 (HK2) and PPARα-mediated glucose transporter downregulation proposed as molecular targets.
How It Works
Unlike conventional antioxidants that indiscriminately neutralize all ROS, hydrogen selectively targets only the most cytotoxic species — hydroxyl radical (•OH) and peroxynitrite — while preserving superoxide and hydrogen peroxide needed for normal cell signaling and immune function. Critically, hydrogen does not interfere with the tumor-killing mechanisms of radiation and chemotherapy.
Hydrogen activates the Nrf2 transcription factor — the master regulator of cellular antioxidant defense. This upregulates protective enzymes (HO-1, NQO1, TXNRD1, GST), reduces ROS levels, inhibits NF-κB nuclear translocation, and creates a protective milieu for normal brain tissue while maintaining tumor-killing capacity of radio-chemotherapy.
RNA sequencing of hydrogen-treated cancer cells revealed activation of TNF/NF-κB signaling and downstream apoptosis, necroptosis, and ferroptosis pathways. Hydrogen paradoxically promotes cancer cell death through inflammatory signaling while protecting normal tissues through antioxidant mechanisms.
In 37 stage IV cancer patients, hydrogen reduced PD-1⁺ terminal CD8⁺ T cells with a 70.3% clinical response rate. Hydrogen activates CoQ10, restoring mitochondrial function in exhausted T cells. In 42 lung cancer patients, H₂ + nivolumab yielded median OS of 28 months vs. 9 months with nivolumab alone.
Clinical Data
The first dedicated clinical study of hydrogen therapy in brain glioma patients enrolled 100 patients randomized to routine treatment alone (n=50) or hydrogen inhalation plus routine treatment (n=50) for two weeks.
| Parameter | Hydrogen Group | Control Group | p Value |
|---|---|---|---|
| Overall clinical efficacy | 90.00% | 72.00% | 0.022 |
| NIHSS score (post-treatment) | 12.19 ± 2.08 | 16.92 ± 2.23 | <0.05 |
| SOD (U/L) | 63.21 ± 5.36 | 52.31 ± 5.24 | <0.05 |
| CAT (U/mL) | 8.01 ± 0.54 | 5.25 ± 0.59 | <0.05 |
| MDA (mmol/L) | 6.05 ± 1.08 | 7.21 ± 1.12 | <0.05 |
| S100β (µg/L) | 0.41 ± 0.09 | 0.66 ± 0.12 | <0.05 |
| NSE (ng/mL) | 8.24 ± 1.64 | 10.67 ± 1.83 | <0.05 |
| E-cadherin (ng/mL) | 0.84 ± 0.05 | 0.72 ± 0.06 | <0.05 |
| Adverse reaction rate | 64.00% | 68.00% | 0.673 |
Hydrogen inhalation significantly improved neurological function, boosted antioxidant enzymes, reduced oxidative damage markers, lowered brain injury biomarkers, and elevated E-cadherin — all without increasing adverse events.
A single-center RCT of 120 glioma patients evaluated perioperative hydrogen/oxygen inhalation versus oxygen alone.
Stony Brook University (New York) is conducting a Phase 2, double-blind, placebo-controlled RCT of hydrogen-rich water in patients with newly diagnosed high-grade gliomas receiving standard Stupp protocol.
Broader Evidence
Significant improvements in fatigue, insomnia, appetite, and pain after 2 weeks. Disease control rates of 83% (stage III) and 47.7% (stage IV). No hematological toxicity. (Chen et al., 2019)
Hydrogen-rich water showed anti-tumor effects comparable to 5-FU in colorectal cancer, and the combination was superior to either alone. (Asgharzadeh et al., 2022)
In 49 liver tumor patients, HRW reduced oxidative stress and improved QoL during RT without compromising anti-tumor efficacy. Also ameliorated bone marrow suppression.
18-hour hydrogen inhalation during CCRT in 10 head/neck cancer patients: zero hydrogen-related adverse events across 33 treatment sessions. (Chitapanarux et al., 2024)
Safety
Clinical Application
| Method | Concentration / Dose | Duration | Setting | Evidence Level |
|---|---|---|---|---|
| H₂ gas inhalation (high-conc.) | 67% H₂ + 33% O₂ | 1 hr, twice daily | Pre-clinical (GBM-specific) | Animal models |
| H₂ gas inhalation (low-conc.) | 2–4% H₂ via nasal cannula | 3–6 hours daily | Clinical (various cancers) | Human studies |
| Perioperative H₂/O₂ | H₂/O₂ mixed gas | During/after surgery | Clinical (glioma) | RCT (n=120) |
| Hydrogen-rich water | 0.5–2.0 ppm; 1.0–1.5 L/day | 6 weeks with RT/TMZ | Clinical (high-grade glioma) | Phase 2 trial |
| Mg tablets in water | ~80 mg Mg → ~2 ppm H₂ | Continuous (outpatient) | Clinical (various) | Multiple trials |
Current Limitations
Future priorities: large multicenter RCTs with Stupp protocol, biomarker-driven patient selection, 6–24 month survival endpoints, combination strategies with TMZ, immunotherapy, and tumor-treating fields.
Peer-Reviewed Sources
This content is for educational and research purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Hydrogen therapy is investigational and should not replace standard-of-care treatment (surgery, radiotherapy, and temozolomide). Always consult your oncology team before considering any adjunctive therapy.